Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197202 | 0.92 | MEN1 (0.62) | KIF11POLBMEN1KMT2ANPC1 | |
| SCHEMBL2974451 | 0.89 | POLB (0.59) | KIF11POLBMEN1KMT2ANPC1 | |
| SCHEMBL3423876 | 0.86 | KIF11 (0.70) | KIF11KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26915 | 0.86 | KIF11 (0.70) | KIF11KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23624571 | 0.84 | NPC1 (0.60) | KIF11POLBMEN1KMT2ANPC1 | |
| SCHEMBL30122815 | 0.84 | PTGS2 (0.52) | KIF11POLBMEN1KMT2ANPC1 | |
| SCHEMBL14666772 | 0.83 | CNR1 (0.51) | KIF11POLBNPC1RAB9ACNR1 | |
| SCHEMBL22870844 | 0.83 | RXRB (0.55) | KIF11POLBMEN1KMT2ACNR1 | |
| Lithium SCHEMBL29536927 | 0.83 | KIF11 (0.67) | KIF11KMT2ANPC1RAB9ASMN1; SMN2 | |
| Lithium SCHEMBL30081449 | 0.83 | KIF11 (0.67) | KIF11KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739062-B2 | Methods for 1,4-diazo N-heterocycle synthesis | PURDUE RESEARCH FOUNDATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739062-B2 | Methods for 1,4-diazo N-heterocycle synthesis | PURDUE RESEARCH FOUNDATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11744145-B2 | Organic compound and organic electroluminescent device comprising the same | LG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-11744145-B2 | Organic compound and organic electroluminescent device comprising the same | LG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-11744145-B2 | Organic compound and organic electroluminescent device comprising the same | LG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-20230159591-A1 | ECHINOCANDIN ANALOGUES AND PREPARATION METHOD THEREFOR | SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-111146349-B | Organic compound and organic electroluminescent device comprising the same | 乐金显示有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20210009533-A1 | New Methods for 1,4-Diazo N-Heterocycle Synthesis | PURDUE RESEARCH FOUNDATION (US) | 2021-01-14 | — | — | US | disclosed |
| US-10800745-B2 | Methods for 1,4-diazo n-heterocycle synthesis | PURDUE RESEARCH FOUNDATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200144506-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | MATERIAL SCIENCE CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
| US-8569522-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130217619-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7453000-B2 | Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-18 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20070149511-A1 | SUBSTITUTED OXAZOLOBENZOISOTHIAZOLE DIOXIDE DERIVATIVES METHOD FOR PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800745-B2 | Methods for 1,4-diazo n-heterocycle synthesis | AOC1, NDC1, DDO | KIF11 3927/4885POLB 2089/4885MEN1 128/4885 |
| US-20070149511-A1 | SUBSTITUTED OXAZOLOBENZOISOTHIAZOLE DIOXIDE DERIVATIVES METHOD FOR PRODUCTION AND USE THEREOF | SLC5A2, SLC5A1, NOX4 | KIF11 3888/4885POLB 2895/4885MEN1 3697/4885 |
| US-20230159591-A1 | ECHINOCANDIN ANALOGUES AND PREPARATION METHOD THEREFOR | ERG28, CYP51A1, WEE1 | KIF11 1010/4885POLB 3610/4885MEN1 47/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | KIF11 4603/4885POLB 2190/4885MEN1 4040/4885 |
| US-11739062-B2 | Methods for 1,4-diazo N-heterocycle synthesis | AOC1, NDC1, DDO | KIF11 3927/4885POLB 2089/4885MEN1 128/4885 |
| US-20130217619-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | KIF11 2982/4885POLB 2435/4885MEN1 3672/4885 |
| US-20210009533-A1 | New Methods for 1,4-Diazo N-Heterocycle Synthesis | NDC1, DDO, AOC1 | KIF11 3904/4885POLB 2333/4885MEN1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.